W H Fridman
Overview
Explore the profile of W H Fridman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
293
Citations
3540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White K, Connor K, Meylan M, Bougouin A, Salvucci M, Bielle F, et al.
Ann Oncol
. 2022 Dec;
34(3):300-314.
PMID: 36494005
Background: New precision medicine therapies are urgently required for glioblastoma (GBM). However, to date, efforts to subtype patients based on molecular profiles have failed to direct treatment strategies. We hypothesised...
2.
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al.
Nat Med
. 2022 May;
28(6):1199-1206.
PMID: 35618839
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in...
3.
Le Cesne A, Marec-Berard P, Blay J, Gaspar N, Bertucci F, Penel N, et al.
Eur J Cancer
. 2019 Aug;
119:151-157.
PMID: 31442817
Purpose: There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. Patients And Methods: This was an open-label, multicentre, phase 2 study of...
4.
Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, et al.
Leukemia
. 2017 Oct;
32(2):558-562.
PMID: 28972593
No abstract available.
5.
Fridman W, Remark R, Goc J, Giraldo N, Becht E, Hammond S, et al.
Int Arch Allergy Immunol
. 2014 May;
164(1):13-26.
PMID: 24852691
Cancer is a major public health issue and figures among the leading causes of death in the world. Cancer development is a long process, involving the mutation, amplification or deletion...
6.
Chauvat A, Benhamouda N, Loison E, Gougeon M, Gey A, Levionnois E, et al.
J Immunol Methods
. 2012 Feb;
378(1-2):81-7.
PMID: 22366633
Monitoring T cells in combination with humoral response may be of value to predict clinical protection and cross-protective immunity after influenza vaccination. Elispot technique which measures cytokine produced after antigen-specific...
7.
Donnou S, Galand C, Daussy C, Crozet L, Fridman W, Sautes-Fridman C, et al.
Clin Exp Immunol
. 2011 Jun;
165(3):329-37.
PMID: 21668435
A large body of evidence indicates that the immune microenvironment controls tumour development. Primary central nervous system lymphomas (PCNSL) are aggressive tumours growing in the central nervous system (CNS). To...
8.
Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al.
Cancer Metastasis Rev
. 2011 Jan;
30(1):83-95.
PMID: 21249423
The immune system regulates angiogenesis in cancer with both pro- and antiangiogenic activities. The induction of angiogenesis is mediated by tumor-associated macrophages and myeloid-derived suppressor cells (MDSC) which produce proinflammatory...
9.
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels J, et al.
Cancer Immunol Immunother
. 2010 Nov;
60(2):261-71.
PMID: 21069322
MUC1 over-expression in renal clear-cell carcinoma (RCC) is associated with poor prognosis. This phase II study determined the efficacy and tolerability of TG4010, a cancer vaccine based on a modified...
10.
Dragon-Durey M, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, et al.
J Med Genet
. 2009 May;
46(7):447-50.
PMID: 19435718
Background: Deletion of the complement factor H related 1 (CFHR1) gene is a consequence of non-allelic homologous recombination and has been reported to be more frequent in atypical haemolytic uraemic...